Business Context and Reporting Period
CytomX Therapeutics, Inc. (CTMX) filed this Form 8-K on March 23, 2020, to report the entry into a Material Definitive Agreement. The company, a Delaware corporation focused on T-cell engaging bi-specific antibody products using its Probody platform, entered into a Collaboration and License Agreement with Astellas Pharma Inc.
Key Financial Metrics and Transaction Terms
This filing details a strategic partnership rather than periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: Astellas will pay CytomX an upfront cash payment of $80 million.
- Milestone Payments: CytomX is eligible to receive future preclinical, clinical, and commercial milestones of approximately $1.6 billion.
- Expansion Option: If Astellas exercises its option to expand the collaboration by up to two additional targets, CytomX could receive an additional aggregate of approximately $0.9 billion in upfront and milestone payments.
- Royalties: Astellas will pay tiered royalties on global net sales ranging from high single-digit to mid-teens percentages.
- Co-Commercialization: If CytomX elects to co-fund clinical trials and co-commercialize in the U.S., it will receive less than 40% of U.S. profits and tiered low double-digit to mid-teens royalties on non-U.S. sales.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Operational Roles
The primary material change is the establishment of a global collaboration framework:
- Scope: Collaboration covers up to four initial targets (expandable to six) for T-cell engaging bi-specific antibodies.
- Development Roles: CytomX leads preclinical research and discovery up to clinical candidate selection. Astellas leads preclinical and clinical development, regulatory approval, and global commercialization.
- Funding: Astellas is responsible for funding preclinical research, discovery, development, manufacture, and commercialization costs, subject to specific co-funding options for CytomX.
- Licensing: CytomX granted Astellas an exclusive, worldwide, royalty-bearing license for the products. Astellas granted CytomX a non-exclusive, royalty-free license for preclinical research and potential U.S. commercialization.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreement. Key risks and contingencies include:
- Termination Rights: Either party may terminate for insolvency, uncured breaches, or patent challenges. Astellas may terminate if a serious safety issue arises or, after the second anniversary, upon notice dependent on the development stage.
- Confidentiality: The full agreement contains confidential portions that will be omitted from the public filing in the upcoming Form 10-Q.
- Future Funding: CytomX has the option to co-fund pivotal studies, which would require capital expenditure subject to caps and offsets.
Investor Verification Checklist
- Verify the receipt of the $80 million upfront payment in the next quarterly cash flow statement.
- Review the full Collaboration and License Agreement filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2020, to understand specific milestone triggers.
- Monitor the selection of the initial four targets and any exercise of the option to expand to six targets.
- Assess the impact of the $80 million cash infusion on the company's liquidity and runway for independent operations.
- Track the timeline for clinical candidate selection to determine when CytomX's lead role transitions to Astellas.